Fluart Innovative Vaccines

Since 1991, we have played a prominent role in the Hungarian healthcare sector, covering 95% of the Hungarian flu market with our vaccines.

Hungary’s only pharmaceutical, biotechnology and life science research company that is a pioneer in influenza vaccine research and production. Through research development projects, we are constantly striving for innovation and development in the field of pharmaceutical and vaccine manufacturing, as well as in various other industries. We are constantly looking for solutions that go beyond treating disease: they have a positive impact on patients’ lives, on society and on science itself. As a Contract Contract Manufacturing Organisation (CDMO), we also provide integrated scientific services, from early discovery through to the production of preclinical/clinical trial samples.

35+

million vaccines produced

90+

qualified staff

History and heritage

The journey so far.

1991
Founding our company as a national manufacturer in Hungary

1991
1994
Influenza vaccine production technology development and commissioning

1994
1995
Production of influenza vaccines begins

1995
1997
Trivalence – development of a three-component influenza vaccine

1997
2005
Successful development of standards for H5N1 reference virus reagents in collaboration with WHO during the avian influenza threat.

2005
2006
Pre- and pandemic vaccine development, licensing

2006
2006 óta
Our products cover about 95% of the Hungarian flu vaccine market (public and pharmacy).

2006 óta
2006
Entering the global market through export sales and Technology Transfer initiatives

2006
2007 óta
The company has a BSL-3 (Bio-Safety Level 3) certified production site environment

2007 óta
2009
Development and production of a new pandemic (H1N1) vaccine

First launched in Europe during the pandemic declared by the WHO

2009
2015
Development and licensing of 3Fluart® trivalent influenza vaccine containing 6 micrograms of the active substance

2015
2015/2016
As a result of continuous development, the company has launched a new seasonal flu vaccine with a significantly reduced active ingredient for the 2015/2016 flu season.

2015/2016
2021
Research and development team expansion

2021
2021
GMP-based manufacturing licence for R&D Pilot plant

2021
2024
Moving to the Pilot research and production facility

2024

Indicator of quality

Research and development and innovation are at the heart of what we do. Our focus is on researching and developing health problems where we have proven expertise and can deliver positive results.

Pioneer approach

A pioneer in the research, production and manufacture of influenza vaccines in Hungary.

Market leader

Hungary’s leading supplier of flu vaccines, exporting Hungarian scientific innovation worldwide.

Quality and safety

We manufacture our vaccines according to GMP regulations and with the approval of the NNGYK, ensuring high quality and safety.

Innovation

We are committed to innovation and research, and are currently working on several new technologies to make disease protection even more effective and affordable.

Social responsibility

We believe in making vaccines available to all. That is why we support vaccination programmes for children and the elderly and are committed to making vaccines affordable for those in need.

Our common future

Our goal is to continue to be a pioneer and leader in the fight against influenza. Towards a future where influenza is no longer a threat and where effective and safe protection is readily available to all.

Scroll to Top